ERBB2 and prostate carcinoma: The most prominently involved pathways for the upregulated proteins were the viral process and ERBB2 signaling (GO; Supplemental Table S3) and EGFR tyrosine kinase inhibitor resistance as well as prostate cancer (KEGG; Supplemental Table S4).